New obesity drug combo aims to boost weight loss
NCT ID NCT07463846
First seen Mar 17, 2026 · Last updated May 02, 2026 · Updated 7 times
Summary
This study tests an experimental drug called ALN-2232, given alone or together with an existing weight-loss medication (tirzepatide), in adults with obesity. The goal is to see if the combination is safe and leads to greater weight loss. About 156 participants with a BMI between 30 and 40 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGMontreal, H3P 3P1, Canada
Conditions
Explore the condition pages connected to this study.